⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NeuroGen Pharma (神基制药) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NeuroGen Pharma (神基制药)
↗Zhuhai, China
NeuroGen Pharma is a China-based biopharmaceutical company established in 2024 through a strategic partnership between CBC Group and Mubadala Investment Company. The company was formed to acquire and operate the mature neurology and allergy product portfolio previously held by UCB in China, including key brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal.
Focused on the central nervous system (CNS) and immunology, NeuroGen aims to address significant unmet medical needs in China. The company operates a fully integrated platform that includes research, production (via a manufacturing site in Zhuhai), and commercialization, positioning itself as a leader in the Chinese neurology market.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS therapeutics, Allergy
SIZE & FINANCIALS
Employees:201-500
Revenue:$100M-$200M
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Backed
Total Raised:$680M
Investors:CBC Group, Mubadala Investment Company
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:UCB (Divestment of mature portfolio), Teva Pharmaceuticals (Partnership for AJOVY in China), Xgene Pharma (Licensing for XG005)
COMPETITION
Position:Challenger
Competitors:Jazz Pharmaceuticals, Sana Biotechnology, C4 Therapeutics
LINKS
Website:neurogen.com.cn
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NeuroGen Pharma (神基制药). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.